Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

AstraZeneca in pact for inhaled drugs

by Michael McCoy
May 8, 2017 | A version of this story appeared in Volume 95, Issue 19

AstraZeneca will pay $57.5 million plus potential milestone payments for access to Pieris Pharmaceuticals’ PRS-060, an engineered protein being developed for respiratory diseases. PRS-060 is what Pieris calls an anticalin, a protein that can mimic antibodies by binding to sites either on other proteins or on small molecules. Unlike an antibody, anticalins can be delivered by inhalation. PRS-060 targets interleukin-4 receptor α, which plays a role in asthma.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.